Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

191.44 +2.44 (+1.29%)
Streaming Delayed Price Updated: 3:07 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge ↗
Vicor Corporation designs advanced power conversion solutions for sectors like aerospace, defense, and industrial automation. 
Via The Motley Fool
News headline image
Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake ↗
Specializing in sports data and analytics, Sportradar serves betting operators, leagues, and media with real-time technology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock ↗
This Arizona-based firm provides factory-built homes and modular units to residential and commercial clients across North America. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year ↗
Globalstar delivers satellite communications and IoT connectivity to enterprise and government clients across critical industries worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies. 
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know ↗
A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter ↗
A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market. 
Via The Motley Fool
News headline image
This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth ↗
One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗
Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings. 
Via Benzinga
News headline image
Ligand (LGND) Q3 2025 Earnings Call Transcript ↗
Ligand (LGND) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗
Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance. 
Via Chartmill
Topics Earnings
News headline image
What's Next: Ligand Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
What Analysts Are Saying About Ligand Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Ligand (LGND) Q2 Revenue Jumps 15% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth ↗
Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month. 
Via Chartmill
News headline image
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts ↗
The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones. 
Via Stocktwits
Topics Government
News headline image
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks. 
Via Benzinga
News headline image
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.